INHIBITION OF C3H-HE MOUSE MAMMARY-TUMOR GROWTH BY COMBINED TREATMENT WITH CYCLOPHOSPHAMIDE AND POLYADENYLIC-POLYURIDYLIC ACID

  • 1 January 1982
    • journal article
    • research article
    • Vol. 42  (11) , 4706-4711
Abstract
The antitumor effect of an immunodulator, polyadenylic-polyuridylic acid, in combination with cyclophosphamide (CY) was studied in C3H/He mice bearing estabished mammary tumors. On Day 14 after graft, mice received either CY (90 mg/kg) alone every 2 wk for a total of 4 inoculations or alternate weekly inoculations of the same dose of CY and polyadenylic-polyuridylic acid (300 .mu.g) or BCG (400 .mu.g) during 8 consecutive wk. On day 170, the following results were obtained. Mice receiving CY alone showed significantly retarded tumor growth; nevertheless, 30 mice of 34 (88%) died of tumor, and only 1 mouse (3%) was tumor free, in mice receiving combined CY and BCG, no more significant tumor inhibition was observed than those receiving CY alone. The most significant tumor inhibition was observed in mice receiving combined CY and polyadenylic-polyuridylic acid. Average tumor diameter on day 63 was 1/3 (2 mm) that of mice receiving CY alone (7 mm); 25 mice of 44 (57%) died of tumor; and 11 mice (25%) were tumor free. The importance of these findings relative to clinical application is considered.